ReFacto®1 and Advate®2: a single‐dose, randomized, two‐period crossover pharmacokinetics study in subjects with haemophilia A
- 29 January 2007
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 13 (2), 124-130
- https://doi.org/10.1111/j.1365-2516.2006.01420.x
Abstract
ReFacto is a recombinant B-domain-deleted, monoclonal antibody-purified, solvent-detergent-treated factor VIII (BDDrFVIII) with no albumin added to the final formulation. Although ReFacto has been shown to be bioequivalent to a plasma-derived FVIII product (Hemophil-M) in a randomized, crossover pharmacokinetic (PK) study, the comparability of ReFacto with the full-length (complete sequence) recombinant FVIII (FLrFVIII, Advate) product has not been previously examined in this manner. The primary objective of this study was to compare the PKs of ReFacto with those of Advate in patients with severe haemophilia A. This was a third-party unblinded, randomized, multicentre, two-period crossover PKs study of ReFacto and Advate in subjects with severe haemophilia A (FVIII:C <= 1%). Blood samples were collected over a 48-h period after i.v. administration of each of the FVIII products. FVIII:C was determined using the chromogenic substrate assay (CSA) in a central laboratory. The plasma FVIII:C PK parameters of ReFacto and Advate were determined using non-compartmental analysis. Bioequivalence was assessed on maximum plasma concentration (C-max) and the area under the plasma concentration vs. time curves (AUCs) using an ANOVA. The two products were judged to be equivalent if the 90% confidence limits of the ratio of the geometric mean values of C-max and AUCs fell within the interval of 80-125%. Results from this PKs comparison of two different rFVIII products, using chromogenic substrate assay to measure FVIII:C, showed that ReFacto and Advate are bioequivalent to each otherKeywords
This publication has 16 references indexed in Scilit:
- The safety and efficacy of B‐domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an updateHaemophilia, 2005
- B‐domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma‐derived factor VIII concentrate: a randomized, three‐way crossover studyHaemophilia, 2005
- Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis - another rebuttal.Haemophilia, 2004
- Meta-analysis on the effectiveness of B-domain deleted factor VIII for prophylaxisHaemophilia, 2003
- Comparative study of full-length and B-domain deleted factor VIII concentratesHaemophilia, 2003
- Controversial use of meta-analysis for factor VIII pharmacokinetic dataHaemophilia, 2003
- Comparative effectiveness of full‐length and B‐domain deleted factor VIII for prophylaxis – a meta‐analysisHaemophilia, 2003
- Preclinical Pharmacology of Albumin-Free B-Domain Deleted Recombinant Factor VIIISeminars in Thrombosis and Hemostasis, 2002
- Structural and functional characterization of B-domain deleted recombinant factor VIIISeminars in Hematology, 2001
- A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity.Proceedings of the National Academy of Sciences of the United States of America, 1986